Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer
Retrieved on:
Thursday, August 31, 2023
AWARD, The New England Journal of Medicine, Medical Affairs Bureau, Cell Metabolism, University, MOA, Therapy, Diabetes, T1D, Diabetes Care, STEP, Coronavirus Scientific Advisory Board, CMO, CDO, Eli Lilly, AML, Morris, Publication, Patient, DSM-IV codes, Cancer, Chief medical informatics officer, DURATION, Amylin Pharmaceuticals, Johnson & Johnson, Safety, Disease, Pharmaceutical industry, Endocrinology, Lancet, Pfizer, Osteopathic medicine in Canada
as Chief Medical Officer (CMO).
Key Points:
- as Chief Medical Officer (CMO).
- Steve Morris, M.D., will transition to the new role of Chief Development Officer (CDO), where he will continue to lead clinical development of Biomea’s oncology portfolio, including BMF-219, BMF-500 and several early-stage oncology research candidates.
- “The addition of Juan to the Biomea Leadership team is an important and exciting event for the company.
- Our appointment of Juan to lead clinical development of BMF-219 in diabetes is a cornerstone of this strategy,” said Thomas Butler, CEO and Chairman of Biomea.